345261-20-3Relevant articles and documents
1,7-Annulated indolocarbazoles as cyclin-dependent kinase inhibitors
Al-Awar, Rima S.,Ray, James E.,Hecker, Kyle A.,Huang, Jianping,Waid, Philip P.,Shih, Chuan,Brooks, Harold B.,Spencer, Charles D.,Watkins, Scott A.,Patel, Bharvin R.,Stamm, Nancy B.,Ogg, Catherine A.,Schultz, Richard M.,Considine, Eileen L.,Faul, Margaret M.,Sullivan, Kevin A.,Kolis, Stanley P.,Grutsch, John L.,Joseph, Sajan
, p. 3217 - 3220 (2004)
The synthesis and kinase inhibitory activity of a series of novel 1,7-annulated indolocarbazoles 6 and 16 is described. These compounds exhibited potent inhibitory activity against cyclin-dependent kinase 4 and good antiproliferative activity in a human colon carcinoma cell line.
Highly Pure Pyrroloquinolinyl-Pyrrole-2,5-Dione and Pyrroloquinolinyl-Pyrrolidine-2,5-Dione and Methods of Preparing Same
-
Paragraph 0125; 0126; 0127, (2013/11/05)
The present invention relates to highly-pure pyrroloquinolinyl-pyrrole-2,5-dione and pyrroloquinolinyl-pyrrolidine-2,5-dione, for example, 3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione, 3-(5,6-dihydro-4H-pyrrolo[
MELEIMIDE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER
-
Page/Page column 53, (2008/06/13)
The present invention relates to pyrroloquinolinyl-pyrrole-2,5-dione compounds and pyrroloquinolinyl-pyrrolidine-2,5-dione compounds, and methods of preparation of these compounds. The present invention also relates to pharmaceutical compositions comprising pyrroloquinolinyl-pyrrole-2,5-dione compounds and pyrroloquinolinyl-pyrrolidine-2,5-dione compounds. The present invention provides methods of treating a cell proliferative disorder, such as a cancer, by administering to a subject in need thereof a therapeutically effective amount of a pyrroloquinolinyl-pyrrole-2,5-dione compound or pyrroloquinolinyl-pyrrolidine-2,5-dione compound of the present invention.